Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SkinJect
Pittsburgh, Pennsylvania, United Statesskinjectpatch.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
SkinJect has completed a Phase 1 trial demonstrating safety and tolerability of its dissolvable doxorubicin microneedle patch in basal cell carcinoma, with some complete responses observed. A randomized, double-blind, placebo-controlled Phase 2 study in nodular basal cell carcinoma is ongoing at multiple US sites; interim data analysis is expected Q1 2025. The technology aims to provide a less invasive alternative to surgery with potential for improved recurrence rates and patient compliance[3][5][7].
- Therapeutic areas
- Oncology
- Modalities
- DeviceSmall molecule (doxorubicin)Biologic (by mechanism, as it induces immune response[8])
- Industry
- Biotech
02
Partnerships
Academic licensing partnership with University of Pittsburgh Innovation Institute[4].No major pharma partnerships disclosed.Key private equity/institutional investors include RBx Capital LP and Velocity Fund Partners[3].
Beyond the preview
Go deeper on SkinJect.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SkinJect.